MedWatch

Almirall closes gap in product portfolio through commercialization agreement with MC2

Spanish dermatology company Almirall's purchase of European rights for MC2 Therapeutics-developed drug gives the company a much-needed treatment for patients suffering from mild or moderate psoriasis.

Photo: Almirall / PR

Last week's license, collaboration and commercialization agreement between Spanish dermatology company Almirall and Danish pharmaceutical firm MC2 Therapeutics on European rights to the drug Wynzora closes a pipeline gap in Almirall's portfolio of treatments for patients with psoriasis.

At the moment, Almirall only has two novel products against psoriasis: Ilumetri and Skilarance, which target severe and moderate-to-severe psoriasis, respectively. The firm will aim Wynzora at mild-to-moderate psoriasis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs